Reports and Data.jpeg-01
Antiviral Drugs Market To Reach USD 71.48 Billion By 2026 | Reports And Data
August 26, 2019 12:14 ET | Reports and Data
New York, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Factors attributed to the growing CAGR and high demand for the antiviral drugs market are higher incidences of HIV and other life-threatening diseases...
plus_logo.png
Plus Therapeutics Reports Q2 2019 Financial and Business Results
August 15, 2019 19:21 ET | Plus Therapeutics, Inc.
AUSTIN, Texas, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced Q2 2019 financial results and provided updates on corporate activities. Q2...
amunix logo.jpg
Amunix Pharmaceuticals Announces the Appointment of Dr. Bryan Irving as Chief Scientific Officer
June 26, 2019 07:05 ET | Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on enabling the promise of potent immune-activating...
CURE Logo.png
CURE Pharmaceutical to Present at the 9th Annual LD Micro Invitational
May 30, 2019 07:25 ET | Cure Pharmaceutical Holding Corp.
LOS ANGELES, May 30, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that it will be presenting at the 9th Annual LD...
logo.png
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May
May 15, 2019 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 15, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating...
amunix logo.jpg
Amunix Expands Executive Team with Appointment of Dr. Mika Derynck as CMO, Dr. Darcy Mootz as CBO, and Yvonne Li as SVP of Finance
May 14, 2019 08:05 ET | Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on the discovery and development of novel protein therapeutics,...
Changfeng Energy Inc..jpg
Changfeng Announces Provincial Approval for the Meishan Integrated District Energy Distribution Project
January 23, 2019 07:27 ET | Changfeng Energy Inc.
TORONTO, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Changfeng Energy Inc., (TSXV: CFY) (“Changfeng” or the “Company”), an energy provider in the People’s Republic of China (the ”PRC”), is pleased to announce...
BioDelivery Sciences logo
BioDelivery Sciences Reports Strong Third Quarter 2018 Financial Results
November 08, 2018 16:05 ET | BioDelivery Sciences International, Inc.
BELBUCA® continued on an accelerated growth trajectory, with revenue increasing 92% YOY and 27% versus prior quarterBELBUCA total prescriptions experienced its largest quarter over quarter increase...
logo-small.jpg
Oblato acquires all rights to glioblastoma drug from OMRF
October 29, 2018 11:21 ET | Oklahoma Medical Research Foundation
OKLAHOMA CITY, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Oblato, Inc., has acquired all rights from the Oklahoma Medical Research Foundation to OKN-007, an investigational drug for the treatment of...
CRBP-300-196.png
Corbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic Fibrosis Lungs at the 2018 North American Cystic Fibrosis Conference
October 18, 2018 16:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Study demonstrates that lenabasum decreases inflammatory biomarkers and increases pro-resolving mediators in airway macrophages from cystic fibrosis patientsCystic fibrosis is a life-threatening...